Series A Momentum EPICS recently secured Series A financing and appointed a new CEO, signaling momentum and readiness to partner to accelerate oncology programs. The company emphasizes high value endpoints and risk sharing in partnerships, making it a strong candidate for out-licensing or co development of preclinical assets and later-stage development.

RNA Epigenetics Focus EPICS targets small molecules interacting with RNA epigenetic mechanisms in cancer, creating a niche that could appeal to pharma partners seeking novel oncology modalities. This biology focus supports options for licensing or collaboration on discovery or preclinical development to complement existing pipelines.

EU Collaboration Potential Belgium-based with a lean team presents opportunities to leverage European funding and incentives. BD outreach could explore co-funded collaborations or grant-supported programs (for example Horizon Europe or IMI) to accelerate asset advancement and share development costs.

Milestone Licensing Model With a lean capital profile and early-stage pipeline, EPICS is well-suited for milestone-driven licensing or out-licensing of assets, minimizing upfront investments for buyers while enabling value capture through clearly defined development milestones.

Past Partnerships & Leadership A history of collaboration (notably with Ogeda) and recent leadership changes signal openness to new partnerships. Engage senior leadership with pipeline updates to explore co-development paths and re-engagement with prior partners.